Group 1 - The core viewpoint of the news is that Tianomab has become the first company to be accepted under the fifth set of listing standards for the Sci-Tech Innovation Board after its resumption, indicating a significant step in the inclusion of unprofitable companies in the market [1][3]. - Tianomab has received investment from seasoned professional institutional investors, specifically from Zhuhai Hillhouse Private Equity Fund Management Co., Ltd., which has been a shareholder since May 2021 [2]. - The company has developed several antibody drugs, with its core product, Staidotamab injection, already approved for market launch, and other candidates in various stages of clinical trials [3]. Group 2 - Tianomab was established in 2015 as an innovative biopharmaceutical company, focusing on the development of antibody drugs [3]. - The company plans to raise 1.5 billion yuan through its IPO, with the funds allocated for new drug research and development, expansion of antibody production facilities, and supplementing working capital [3]. - The company has invested over 1.1 billion yuan in research and development from 2022 to 2024, highlighting its commitment to innovation in the biopharmaceutical sector [3].
科创板第五套标准重启后 首家受理企业来了
Zhong Guo Zheng Quan Bao·2025-07-31 15:03